Lunit’s SCOPE IO artificial intelligence (AI)-based pathology platform has demonstrated its ability to generate biomarkers that predict patients’ response to immunotherapy across cancer types.

Data from three studies are being debuted by the South Korean company in presentations at this year’s European Society for Medical Oncology (ESMO) congress, taking place from October 17–21 in Berlin, Germany.

For the AtezoTRIBE and AVETRIC trials, conducted at the University of Pisa in Italy, SCOPE IO was applied to pre-treatment histology slides from enrolled patients with proficient mismatch repair (pMMR) metastatic colorectal cancer (mCRC). Lunit’s AI platform generated a biomarker that stratified patients into “biomarker-high” and “biomarker-low” groups in the respective trials.